Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

WTX 124

Next Previous
Drug Profile

WTX 124

Alternative Names: WTX-124

Latest Information Update: 28 Aug 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Werewolf Therapeutics
  • Class Antineoplastics; Immunotherapies; Interleukins
  • Mechanism of Action Interleukin 2 replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 28 Aug 2025 WTX 124 is still in phase I development in Solid-tumours (Combination therapy, Monotherapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (IV) (NCT05479812)
  • 14 Aug 2025 Werewolf Therapeutics plans to meet with the US FDA to discuss potential registrational pathways for WTX 124 in Cutaneous melanoma (Late stage disease, Metastatic disease), in the second half of 2025
  • 28 Jul 2025 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (IV)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top